Navigation Links
Trovagene, Inc. Reports Third Quarter 2013 Financial Results

SAN DIEGO, Nov. 14, 2013 /PRNewswire/ -- Trovagene, Inc. (NASDAQ:  TROV), a developer of cell-free molecular diagnostics, today reported financial results for the three months and the nine months ended September 30, 2013.


"We have made significant corporate and scientific achievements in recent months. We have signed multiple collaboration agreements and launched our first oncogene mutation detection test. In addition, the first series of clinical results were presented at a major medical conference. These data demonstrated the detection and monitoring of cancer mutations in urine with high rates of sensitivity," stated Antonius Schuh, Ph.D., chief executive officer of Trovagene. "Trovagene is well positioned to leverage its investment in its intellectual property, scientific research, and collaborations to build a better clinical pathway for cancer monitoring."

Third Quarter 2013 Financial Results
For the three months ended September 30, 2013, Trovagene reported a net loss available to common stockholders of $4.4 million, or $0.25 per share, as compared to a net loss available to common stockholders of $0.66 million, or $0.05 per share, for the three months ended September 30, 2012. The increase in net loss available to common stockholders was primarily due to an increase in total operating expenses of $1.87 million, or $0.10 per share, as well as an increase in the change in fair value of derivative instruments related to warrants of $1.71 million, $0.09 per share, during the third quarter of 2013, as compared to the prior year comparable period.

First Nine Months Financial Results
For the nine months ended September 30, 2013, Trovagene reported a net loss available to common stockholders of $10.8 million, or $0.66 per share, as compared to a net loss available to common stockholders of $5.3 million, or $0.42 per share, for the nine months ended September 30, 2012. The increase in net loss available to common stockholders is primarily attributable to an increase in total operating expenses of $4.4 million, or $0.27 per share, and an increase in the change in fair value of derivative instruments related to warrants of $1.1 million, $0.07 per share, as compared to the prior year comparable period.

Cash and Cash Equivalents
Trovagene had cash and cash equivalents of approximately $28 million at September 30, 2013, as compared to $11 million at December 31, 2012. The Company completed a $15 million registered direct offering on July 31, 2013.

Review of Recent 2013 Announcements Demonstrate Progress in Development Programs

  • Presented first prospective cancer monitoring data demonstrating that Trovagene's diagnostics can detect rare oncogene mutation signals in urine that closely correlate to tissue biopsy and response to therapy.
  • Launched cell-free BRAF oncogene diagnostic, the first urine-based cancer mutation monitoring test.
  • Entered into collaboration with an undisclosed pharmaceutical company to study oncogene detection and monitoring in lung cancer. Initiated clinical collaboration with USC Norris Cancer Center to study genomic characterizations of metastatic colorectal cancers using Trovagene's proprietary cell-free DNA assays.
  • Completed $15 million registered direct offering of common stock.
  • Webcast of Earnings Conference Call
    Trovagene's management team will host an earnings conference call on Thursday, November 14, 2013, at 5:00 p.m. Eastern Standard Time (2:00 p.m. Pacific Standard Time). Interested parties may listen to a live audio broadcast of the conference call on the Company's website in the Investor Room. A replay of the call can be accessed approximately one hour after the completion of the call and will be archived on the website for at least one year.

    About Trovagene, Inc.
    Headquartered in San Diego, California, Trovagene is leveraging its patented technology for the detection of cell-free DNA and RNA, short nucleic acid fragments, originating from normal and diseased cell death that can be isolated and detected from urine. Trovagene has a strong intellectual property asset as it relates to cell-free DNA and RNA testing in urine. It has U.S. and European patent applications and issued patents that cover testing for HPV and other infectious diseases, cancer, transplantation, prenatal and genetic testing.

    Certain statements in this press release are forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995. These statements may be identified by the use of forward-looking words such as "anticipate," "believe," "forecast," "estimated" and "intend," among others. These forward-looking statements are based on Trovagene's current expectations and actual results could differ materially. There are a number of factors that could cause actual events to differ materially from those indicated by such forward-looking statements. These factors include, but are not limited to, substantial competition; our ability to continue as a going concern; our need for additional financing; uncertainties of patent protection and litigation; uncertainties of government or fourth party payer reimbursement; limited sales and marketing efforts and dependence upon fourth parties; and risks related to failure to obtain FDA clearances or approvals and noncompliance with FDA regulations. As with any medical diagnostic tests under development, there are significant risks in the development, regulatory approval and commercialization of new products. There are no guarantees that future clinical trials discussed in this press release will be completed or successful or that any product will receive regulatory approval for any indication or prove to be commercially successful. Trovagene does not undertake an obligation to update or revise any forward-looking statement.  Investors should read the risk factors set forth in Trovagene's Form 10-K for the year ended December 31, 2012 and other periodic reports filed with the Securities and Exchange Commission.

     (Financial Information to Follow)ContactTrovagene, Inc.FinancialInvestor RelationsStephen Zaniboni

    Chief Financial OfficerAmy Caterina

    Investor RelationsTrovagene, Inc.Trovagene, 



    Trovagene, Inc. and Subsidiaries
    (A Development Stage Company)
    Selected Financial Information
    Consolidated Condensed Statements of Operations and Comprehensive Loss 

    (in thousands, except for per share amounts) Three Months Ended
    September 30,Nine Months Ended
    September 30,2013201220132012(Unaudited)(Unaudited)Revenues$




    287Operating expenses:Research and development 9165112,6621,326General and administrative 2,2067395,3922,376Total operating expenses3,1221,2508,0533,702Operating loss(3,078)(1,039)(7,842)(3,415)Interest expense(6)-(7)-Change in fair value of derivative instruments - warrants(1,317)389(2,933) 

    (1,824)Net loss and comprehensive loss$




    (5,239)Preferred stock dividend(5)(10)(21)(29)Net loss and comprehensive loss available to common stockholders$




    (5,268)Basic and diluted net loss per share$




    (0.42)Weighted average shares outstanding- basic and dilute17,87114,17816,33012,507 




    Trovagene, Inc. and Subsidiaries(A Development Stage Company)Consolidated Condensed Balance Sheet Information (in thousands) September 30,
    2013December 31,
    2012(Unaudited) Cash and cash equivalents$


    10,820Other assets611590Property and equipment, net740255Total assets$


    11,665Current portion of long-term debt$


    -Accounts payable, accrued expenses and other liabilities1,213730Long-term debt, less current portion370-Derivative financial instruments6,2818,766Stockholders' equity 21,1382,169Total liabilities and stockholders' equity$



    SOURCE Trovagene, Inc.
    Copyright©2012 PR Newswire.
    All rights reserved

    Related biology technology :

    1. TrovaGene, Inc. Obtains Exclusive License to Novel Mutations Associated with Prognosis and Chemotherapy Response in Leukemia
    2. Trovagene, Inc. Announces Full Exercise of Over-Allotment Option by Aegis Capital Corp.
    3. Discovery Labs Reports Third Quarter Financial Results and Progress on Lead Programs
    4. Verenium Reports Financial Results for the Third Quarter and Nine Months Ended September 30, 2011
    5. Interleukin Genetics Reports Third Quarter 2011 Financial Results
    6. Cell Therapeutics, Inc. Reports Results of Annual Meeting of Shareholders
    7. Nile Therapeutics Reports 2011 Third Quarter Financial Results
    8. Pharmasset Reports Fiscal Year End 2011 Financial Results
    9. Palatin Technologies, Inc. Reports First Quarter Fiscal Year 2012 Results; Teleconference and Webcast to be held on November 15, 2011
    10. SeraCare Reports Fiscal Year 2011 and Fourth Quarter Financial Results
    11. WaferGen Reports Third Quarter 2011 Financial Results and Announces New Commercialization Strategy
    Post Your Comments:
    (Date:11/25/2015)... Studies reveal the differences in species of bacteria ... for more effective treatment for one of the most commonly ... --> --> Gum disease is one ... relatively little was understood about the bacteria associated with it ... researchers from the WALTHAM Centre for Pet Nutrition together with ...
    (Date:11/25/2015)... , ... November 25, 2015 , ... ... the Organization of Black Aerospace Professionals (OPBAP) has been formalized with the signing ... AMA team leaders met with OPBAP leaders Capt. Karl Minter and Capt. Albert ...
    (Date:11/24/2015)... Nov. 24, 2015  Asia-Pacific (APAC) holds the ... (CRO) market. The trend of outsourcing to low-cost ... but higher volume share for the region in ... however, margins in the CRO industry will improve. ... ( ), finds that the market ...
    (Date:11/24/2015)... /CNW/ - iCo Therapeutics ("iCo" or "the Company") (TSX-V: ... the quarter ended September 30, 2015. Amounts, unless ... presented under International Financial Reporting Standards ("IFRS"). ... Andrew Rae , President & CEO of ... only value enriching for this clinical program, but ...
    Breaking Biology Technology:
    (Date:11/16/2015)... 2015  Synaptics Inc. (NASDAQ: SYNA ), ... announced expansion of its TDDI product portfolio with ... and display driver integration (TDDI) solutions designed to ... TDDI products add to the previously-announced TD4300 ... resolution), and TD4322 (FHD resolution) solutions. All four ...
    (Date:11/10/2015)... 10, 2015  In this report, the ... of product, type, application, disease indication, and ... report are consumables, services, software. The type ... biomarkers, efficacy biomarkers, and validation biomarkers. The ... diagnostics development, drug discovery and development, personalized ...
    (Date:11/2/2015)... Nov. 2, 2015  SRI International has been awarded ... preclinical development services to the National Cancer Institute (NCI) ... provide scientific expertise, modern testing and support facilities, and ... pharmacology and toxicology studies to evaluate potential cancer prevention ... The PREVENT Cancer Drug Development Program is an NCI-supported ...
    Breaking Biology News(10 mins):